Regencell Bioscience (NASDAQ:RGC) Trading Up 5.4% – Here’s What Happened

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) were up 5.4% during mid-day trading on Thursday . The company traded as high as $17.39 and last traded at $17.25. Approximately 41,814 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 7,604,027 shares. The stock had previously closed at $16.36.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The business’s 50 day moving average is $15.05.

Institutional Investors Weigh In On Regencell Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after acquiring an additional 384,250 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Regencell Bioscience during the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the second quarter worth approximately $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience during the third quarter worth approximately $598,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Regencell Bioscience in the second quarter valued at approximately $222,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.